Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

Trial Profile

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Carboplatin (Primary) ; LAG 525 (Primary) ; Spartalizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2018 Planned End Date changed from 8 Dec 2020 to 20 Apr 2021.
    • 06 Dec 2018 Planned primary completion date changed from 26 Dec 2019 to 7 May 2020.
    • 08 Aug 2018 According to an Immutep Limited media release, the enrollment of patients in this study are expected to initiate in 3Q 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top